Top

BY Clayton Boldt, Ph. D.

Each year in the U.S., more than 50,000 people will be diagnosed with pancreatic cancer, which ranks around the 10th most common cancer type. However, it is the third leading cause of cancer death, behind only lung and colorectal cancers.

For Pancreatic Cancer Awareness Month, Cancer Frontline spoke with Anirban Maitra, M.B.B.S., scientific director of the Sheikh Ahmed Pancreatic Cancer Research Center, about important ongoing...

Pancreatic Cancer Moon Shot co-leader Anirban Maitra, M.B.B.S., leads the GENERATE clinical trial, a cutting-edge risk-assessment effort that offers genetic testing to people who have a close relative diagnosed with pancreatic cancer.

BY Clayton Boldt, Ph. D.

Repurposing FDA-approved therapies is a cost-effective way to bring new treatments to patients in need, but identifying those drugs with benefits...

BY Scott Merville

Using an antibody to plug a protein secreted by fibrous tissues in tumors stifles ovarian and pancreatic cancer in mouse models by reducing...

BY Ron Gilmore

Just as a driver’s night vision improves by simply cleaning the headlights, scientists at The University of Texas MD Anderson Cancer Center have discovered that removing an unwanted element from a protein known to suppress the immune system may eventually help clinicians better observe which cancer patients will benefit by treatment with immune checkpoint blockades.

Heng-Huan Lee, Ph.D., a postdoctoral fellow and Ying-Nai Wang,...

Glycans attach to the PD-L1 protein on tumors, making it hard to detect. MD Anderson researchers have found that purging glycans makes PD-L1 easier to find and accurately assess. Image courtesy of Cancer Cell.

BY Jill Russell, Ph.D.

Researchers at The University of Texas MD Anderson Cancer Center have shown how pretreatment clonal complexity in pancreatic tumor cells leads...

BY Jill Russell, Ph.D.

Unresectable pancreatic cancer is usually fatal because other treatments, such as radiation therapy, cannot be used. Radiation therapy causes...

BY Clayton R. Boldt, Ph.D.

Neoadjuvant therapy is treatment, such as chemotherapy or radiation, given before a patient has surgery. This approach is used in many cancer...

BY Clayton R. Boldt, Ph.D.

MD Anderson’s proteomics platform provides a valuable institutional resource, complete with state-of-the-art instruments and specialized expertise...

BY MD Anderson staff

This is the second part of Cancer Frontline’s interview with Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology...

BY MD Anderson staff

In October 2018, the Nobel Prize in Physiology or Medicine was awarded to Jim Allison, Ph.D., chair of Immunology, for his discoveries on...